Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 20 de 2366 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Comoretto RI, Rea F, Lucenteforte E, Mugelli A, Trifirò G, Cascini S, Roberto G, Chinellato A, Filippelli A, Corrao G, on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. Eur J Clin Pharmacol 2018;74:1061-70. [Ref.ID 102823]
2.Enlace a cita original Cita con resumen
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018;361:4 de julio. [Ref.ID 102751]
4.Enlace a cita original Cita con resumen
Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]
5. Cita con resumen
Anónimo. Edoxaban: Interstitial lung disease. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102620]
6.Enlace a cita original Cita con resumen
Hart RG, Sharma M, Mundl H, Kasner SE, Bagdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonskowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS Investigators. Ribaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201. [Ref.ID 102610]
8. Cita con resumen
Anónimo. Outbreak Alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention 2018:5 de abril. [Ref.ID 102503]
9. Cita con resumen
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 2017;167:845-54. [Ref.ID 102196]
10.Enlace a cita original Cita con resumen
Uyhazi KE, Miano T, Pan W, VanderBeek BL. Association of novel oral antithrombotics with the risk of intraocular bleeding. Jama Ophthalmol 2017:14 de diciembre. [Ref.ID 102190]
11. Cita con resumen
Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017;377:2228-39. [Ref.ID 102165]
12. Cita con resumen
López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovic J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017;359:j5058. [Ref.ID 102157]
13. Cita con resumen
Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]
14. Cita con resumen
Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a french nationwide cohort study. Pharmacoepidemiol Drug Saf 2017;26:1367-77. [Ref.ID 102133]
15. Cita con resumen
Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 2017;73:1417-25. [Ref.ID 102130]
16. Cita con resumen
Fanning L, Ilomäki J, Bell JS, Darzinš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol 2017;73:1427-36. [Ref.ID 102129]
17. Cita con resumen
Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]
18. Cita con resumen
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]
19. Cita con resumen
Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]
20. Cita con resumen
Sugiyama T. Osteoporotic fractures associated with dabigatran vs warfarin. JAMA 2017;318:90-1. [Ref.ID 102054]
Seleccionar todas
 
 1 a 20 de 2366 siguiente >>